Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
2.175 EUR | -0.68% | +0.23% | -16.98% |
Mar. 21 | Transcript : Innate Pharma S.A., 2023 Earnings Call, Mar 21, 2024 | |
Mar. 06 | Innate Pharma initiates lymphoma trial | CF |
Sales 2023 | 61.64M 66.52M | Sales 2024 * | 47.99M 51.78M | Capitalization | 177M 191M |
---|---|---|---|---|---|
Net income 2023 | -7M -7.55M | Net income 2024 * | -29M -31.3M | EV / Sales 2023 | 3.43 x |
Net cash position 2023 * | 29.41M 31.74M | Net cash position 2024 * | 25.2M 27.19M | EV / Sales 2024 * | 3.16 x |
P/E ratio 2023 |
-29.1
x | P/E ratio 2024 * |
10.4
x | Employees | 191 |
Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 75.5% |
Latest transcript on Innate Pharma
1 day | +0.46% | ||
1 week | +1.38% | ||
Current month | +0.69% | ||
1 month | -6.78% | ||
3 months | -14.06% | ||
6 months | -13.39% | ||
Current year | -16.03% |
Managers | Title | Age | Since |
---|---|---|---|
Eric Vivier
FOU | Founder | 59 | 99-09-22 |
Chief Executive Officer | 62 | 99-09-22 | |
Frederic Lombard
DFI | Director of Finance/CFO | 49 | 21-03-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 62 | 99-09-22 | |
Gilles Brisson
BRD | Director/Board Member | 72 | 07-06-25 |
Olivier Martinez
BRD | Director/Board Member | 54 | 10-05-24 |
Date | Price | Change | Volume |
---|---|---|---|
24-03-28 | 2.175 | -0.68% | 30 006 |
24-03-27 | 2.19 | -0.23% | 53,254 |
24-03-26 | 2.195 | +0.69% | 26,812 |
24-03-25 | 2.18 | +0.69% | 32,842 |
24-03-22 | 2.165 | -0.23% | 25,864 |
Real-time Euronext Paris, March 28, 2024 at 04:07 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-16.03% | 192M | |
+9.16% | 45.97B | |
+53.58% | 43.93B | |
+11.20% | 42.34B | |
-8.59% | 28.27B | |
+16.40% | 27.18B | |
-19.34% | 19.44B | |
+13.95% | 13.83B | |
+31.56% | 12.4B | |
+10.63% | 11.45B |